Article
miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
Journal of clinical pathology - 1 Mar 2014
Pichler Martin, Winter Elke, Ress Anna Lena, Bauernhofer Thomas, Gerger Armin, Kiesslich Tobias, Lax Sigurd, Samonigg Hellmut, Hoefler Gerald
Abstract excerpt
AIMS: miR-181a expression is frequently altered in different types of cancer. Members of the Wnt/β-catenin signalling pathway, which is commonly altered in colorectal cancer (CRC), have been reported as molecular interaction partners of miR-181. However, the role of miR-181a expression in CRC and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
